selinexor + carmustine + etoposide + cytarabine + melphalan

This is a combination chemotherapy regimen consisting of five agents: - **Selinexor** is a first-in-class, selective oral inhibitor of exportin 1 (XPO1), which leads to nuclear accumulation and reactivation of tumor suppressor proteins such as p53 and p21, and reduction in oncoproteins including c-MYC, BCL2, and BCL6. It is primarily used in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and multiple myeloma[7]. - **Carmustine**, **etoposide**, **cytarabine**, and **melphalan** together form the BEAM regimen, which is an established high-dose chemotherapy protocol used as a preparative (conditioning) regimen for autologous or allogeneic stem cell transplantation in lymphoma patients[1][2][3]. Each drug has distinct mechanisms targeting DNA synthesis or function. The addition of selinexor to the BEAM backbone represents an investigational approach aiming to enhance anti-tumor efficacy by combining targeted nuclear export inhibition with multi-agent cytotoxic chemotherapy.